Patents by Inventor Richard M. Kinney
Richard M. Kinney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230181682Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: ApplicationFiled: December 12, 2022Publication date: June 15, 2023Applicants: TAKEDA VACCINES INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARYInventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
-
Publication number: 20220062375Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: ApplicationFiled: September 17, 2021Publication date: March 3, 2022Applicants: TAKEDA VACCINES, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENTInventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
-
Publication number: 20200061151Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: ApplicationFiled: September 5, 2019Publication date: February 27, 2020Inventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
-
Patent number: 10449231Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: GrantFiled: April 20, 2017Date of Patent: October 22, 2019Assignees: TAKEDA VACCINES, INC., The Government of the United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
-
Patent number: 10335478Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: September 6, 2016Date of Patent: July 2, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Mahidol UniversityInventors: Richard M. Kinney, Claire Y. H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Publication number: 20170290884Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: ApplicationFiled: April 20, 2017Publication date: October 12, 2017Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
-
Patent number: 9783579Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: GrantFiled: March 13, 2014Date of Patent: October 10, 2017Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Dan T. Stinchcomb, Claire Kinney, Richard M Kinney, Jill A Livengood
-
Publication number: 20160367658Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: September 6, 2016Publication date: December 22, 2016Applicants: The Government of the USA, as represented by the Secretary, Department of Health and Human Services, Mahidol UniversityInventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Patent number: 9463233Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: January 28, 2014Date of Patent: October 11, 2016Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Mahidol UniversityInventors: Richard M. Kinney, Claire Y. H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Publication number: 20140302088Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: ApplicationFiled: March 13, 2014Publication date: October 9, 2014Applicants: The Government of the United States of America as Represented by the Secretar, INVIRAGEN, INC.Inventors: Daniel T. Stinchcomb, Claire Y Huang, Richard M Kinney, Jill A Livengood
-
Publication number: 20140141040Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicants: Mahidol University, The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Patent number: 8715689Abstract: The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.Type: GrantFiled: April 27, 2009Date of Patent: May 6, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Claire Y. H. Kinney, Eric Thomas Beck, Richard M. Kinney
-
Patent number: 8673316Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: August 18, 2011Date of Patent: March 18, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention, Mahidol UniversityInventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Publication number: 20120014981Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: August 18, 2011Publication date: January 19, 2012Inventors: Richard M. Kinney, Claire Y.H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Patent number: 8025887Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: October 28, 2009Date of Patent: September 27, 2011Assignees: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention, Mahidol UniversityInventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Publication number: 20110150771Abstract: The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.Type: ApplicationFiled: April 27, 2009Publication date: June 23, 2011Inventors: Claire Y.H. Kinney, Eric Thomas Beck, Richard M. Kinney
-
Publication number: 20100255030Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: October 28, 2009Publication date: October 7, 2010Inventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Patent number: 7641909Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: August 18, 2006Date of Patent: January 5, 2010Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services, Certers for Disease Control and PreventionInventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Publication number: 20090010961Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: August 18, 2006Publication date: January 8, 2009Inventors: Richard M. Kinney, Claire Y.H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Patent number: 7094411Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: February 16, 2001Date of Patent: August 22, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati